GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (MEX:INO) » Definitions » Cyclically Adjusted PS Ratio

Inovio Pharmaceuticals (MEX:INO) Cyclically Adjusted PS Ratio : (As of Jun. 24, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Inovio Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Inovio Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Inovio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.84 27.98 16.59 5.05 1.81

Inovio Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.65 1.44 1.35 1.81 -

Competitive Comparison of Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Inovio Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Inovio Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Inovio Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Inovio Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 9.784 100.560 12.821
201409 4.892 100.428 6.419
201412 7.150 99.070 9.510
201503 15.518 99.621 20.527
201506 14.674 100.684 19.205
201509 66.306 100.392 87.035
201512 16.916 99.792 22.338
201603 23.194 100.470 30.421
201606 18.871 101.688 24.455
201609 39.432 101.861 51.013
201612 28.440 101.863 36.792
201703 31.552 102.862 40.421
201706 58.715 103.349 74.865
201709 6.614 104.136 8.370
201712 22.872 104.011 28.978
201803 3.687 105.290 4.615
201806 63.187 106.317 78.318
201809 4.860 106.507 6.013
201812 6.136 105.998 7.628
201903 6.756 107.251 8.301
201906 0.320 108.070 0.390
201909 1.998 108.329 2.430
201912 0.630 108.420 0.766
202003 2.996 108.902 3.625
202006 0.475 108.767 0.575
202009 0.359 109.815 0.431
202012 7.633 109.897 9.153
202103 0.450 111.754 0.531
202106 0.311 114.631 0.358
202109 0.343 115.734 0.391
202112 0.970 117.630 1.087
202203 0.217 121.301 0.236
202206 0.804 125.017 0.847
202209 8.861 125.227 9.324
202212 0.117 125.222 0.123
202303 0.096 127.348 0.099
202306 0.176 128.729 0.180
202309 0.302 129.860 0.306
202312 0.077 129.419 0.078
202403 0.000 131.776 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Inovio Pharmaceuticals  (MEX:INO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Inovio Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Inovio Pharmaceuticals (MEX:INO) Business Description

Traded in Other Exchanges
Address
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.